Vaccine Info

Diamyd Type 1 Diabetes Vaccine

Authored by
Last reviewed
March 4, 2021
Fact checked by
Robert Carlson, MD

Diamyd Type 1 Diabetes Vaccine Description

Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production.  Recombinant GAD65 is the active ingredient in the therapeutic diabetes vaccine.

Diamyd Type 1 Diabetes Vaccine Indication

Diamyd is indicated for individuals recently diagnosed with type 1 diabetes who carry the genetic HLA DR3-DQ2 haplotype.

Diamyd Type 1 Diabetes Vaccine News

March 4, 2021 - Diamyd Medical announced an update on the Phase 3 clinical trial of their Type 1 diabetes vaccine. ”We are breaking new ground and with this comprehensive data package very excited to advance the first-ever precision medicine approach for type 1 diabetes”, said Ulf Hannelius, CEO of Diamyd Medical.

Diamyd Type 1 Diabetes Vaccine Clinical

Clinical Trial NCT00435981: Phase 2 trial Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes (Completed)

This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta-cell function in children and adolescents with type 1 diabetes with diabetes diagnosis duration less than 18 months at intervention.

Clinical Trial NCT02352974: Phase 1 trial GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1) (DIAGNODE) - Last Update Posted on April 27, 2020.



Clinical Trials

No clinical trials found